Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Long-Term Investments (2022 - 2024)

Zentalis Pharmaceuticals has reported Long-Term Investments over the past 3 years, most recently at $349.9 million for Q3 2024.

  • Quarterly results put Long-Term Investments at $349.9 million for Q3 2024, changed N/A from a year ago — trailing twelve months through Sep 2024 was $349.9 million (changed N/A YoY), and the annual figure for FY2023 was $454.9 million, up 2044.35%.
  • Long-Term Investments for Q3 2024 was $349.9 million at Zentalis Pharmaceuticals, down from $389.4 million in the prior quarter.
  • Over the last five years, Long-Term Investments for ZNTL hit a ceiling of $454.9 million in Q4 2023 and a floor of $18.9 million in Q1 2023.
  • Median Long-Term Investments over the past 3 years was $35.7 million (2022), compared with a mean of $197.8 million.
  • Biggest five-year swings in Long-Term Investments: plummeted 47.05% in 2023 and later skyrocketed 2287.81% in 2024.
  • Zentalis Pharmaceuticals' Long-Term Investments stood at $21.2 million in 2022, then soared by 2044.35% to $454.9 million in 2023, then dropped by 23.07% to $349.9 million in 2024.
  • The last three reported values for Long-Term Investments were $349.9 million (Q3 2024), $389.4 million (Q2 2024), and $451.4 million (Q1 2024) per Business Quant data.